CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Daclatasvir

Last Updated: February 13, 2015
Result type: Reports
Project Number: SR0417-000
Product Line: Reimbursement Review

Generic Name: Daclatasvir

Brand Name: Daklinza

Manufacturer: Bristol-Myers Squibb Canada Inc.

Indications: Hepatitis C, chronic

Submission Type: Pre-NOC

Project Status: Complete

Date Recommendation Issued: September 21, 2015

Recommendation Type: List with clinical criteria and/or conditions